Recent years, we have witnessed significant progresses in both basic and clinical studies
regarding novel therapeutic strategies with genetically engineered T cells. Modification with …

Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring
outcomes in patients with B cell malignancies, and are now being investigated in other …

Abstract The first CD19 CAR T-cell products, Kymriah and Yescarta, are entering the US
market and also being evaluated for marketing authorization in the EU. This breakthrough …

This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …

Chimeric antigen receptors (CARs) are genetically engineered receptors that provide
specific properties to an immune effector cell and these receptors gain the specificity of a …

T cells genetically targeted with a chimeric antigen receptor (CAR) to B-cell malignancies
have demonstrated tremendous clinical outcomes. With the proof in principle for CAR T cells …

Chimeric antigen receptor T (CAR-T) cell therapy is regarded as an effective solution for
relapsed or refractory tumors, particularly for hematological malignancies. Although the …

Background: Chimeric antigen receptor (CAR)-modified T cells have successfully harnessed
T cell immunity against malignancies, but they are by no means the only cell therapies in …

Blockbuster antibody therapies have catapulted immune‐based approaches to treat cancer
into the consciousness of mainstay clinical research. On the back of this, other emerging …

Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic
agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric …